Cytori Therapeutics (NASDAQ:CYTX)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Tuesday, September 18th. They presently have a $5.00 target price on the biotechnology company’s stock.
The analysts wrote, “Our valuation for Cytori is based on success with the current therapeutics pipeline with probability of success factors weighted in each therapeutic area. These forecasts feed into our valuation metrics, of free cash flow to the firm (FCFF), discounted EPS (dEPS) and sum- of-the-parts (SOP) models.””
A number of other analysts also recently issued reports on the stock. ValuEngine raised shares of Cytori Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, September 4th. Maxim Group downgraded shares of Cytori Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, August 15th. Finally, Zacks Investment Research raised shares of Cytori Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price objective for the company in a report on Tuesday, July 31st. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. Cytori Therapeutics presently has an average rating of “Buy” and an average price target of $10.56.
Cytori Therapeutics (NASDAQ:CYTX) last announced its quarterly earnings results on Tuesday, August 14th. The biotechnology company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.50) by ($0.09). Cytori Therapeutics had a negative net margin of 380.64% and a negative return on equity of 202.09%. The firm had revenue of $1.56 million during the quarter, compared to the consensus estimate of $2.50 million. As a group, sell-side analysts forecast that Cytori Therapeutics will post -0.85 earnings per share for the current fiscal year.
About Cytori Therapeutics
Cytori Therapeutics, Inc, a therapeutics company, together with its subsidiaries, develops regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for various medical conditions. Its lead drug candidate, ATI-0918, is a generic version of pegylated liposomal encapsulated doxorubicin, which is in Phase III clinical trial and used for various cancer types.
Receive News & Ratings for Cytori Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.